AIOMEGA launches Breathe Academy for clinician training on FDA-cleared OSA devices

AIOMEGA said Oct. 1 it is rolling out a national training program for clinicians using its FDA-cleared adult and pediatric wearable oral devices for obstructive sleep apnea. The Academy is meant to standardize prescribing, documentation and implementation across sleep centers, ENT, dental sleep and pediatric care settings.

Why it matters: - AIOMEGA is trying to make its obstructive sleep apnea treatment pathways easier for clinicians to adopt across adult and pediatric care. - The program could broaden use of FDA-cleared wearable oral devices in settings that treat sleep-disordered breathing. - AIOMEGA is pairing device training with clinician guidance tools, which may help standardize prescriptions and follow-up.

What happened: - AIOMEGA LLC announced the national release of the AIOMEGA Breathe Academy on Oct. 1, 2026. - The Academy is a clinician training program for the company’s FDA-cleared adult and pediatric wearable oral devices for airway stabilization. - The program is aimed at hospital systems, sleep centers, ENT practices, dental sleep medicine providers, orthodontists and dentists specialized in TMD. - The launch comes as AIOMEGA says clinical adoption of its adult and pediatric obstructive sleep apnea pathways is growing.

The details: - AIO Breathe is the adult device, cleared under FDA 510(k) K233754 to reduce or alleviate snoring and mild to moderate obstructive sleep apnea in adults while sleeping. - AIO Breathe PDS is the pediatric device, cleared under FDA 510(k) K252525 to reduce snoring and treat mild and moderate obstructive sleep apnea in children ages 6 to 17. - AIOMEGA said the Academy is built around the two FDA-cleared wearable oral devices and the clinician-directed prescription tools that support their use. - The adult pathway uses a clinician-controlled prescription model and a non-titration treatment approach. - The adult device does not require a morning repositioner, according to the FDA clearance language cited in the release. - The pediatric device is designed for growth-responsive alignment and sequential airflow improvement during craniofacial development. - Clinicians may specify a posterior leaning flange angle greater than 90 degrees when prescribing AIO Breathe devices. - AIOMEGA said the posterior leaning flange option does not change the device and is part of the FDA-cleared design. - The Academy includes training on AIO Rx, SMART Rx and the combined AIOMEGA Clinical Guidance System. - AIO Rx covers mandibular advancement, vertical opening, plateau height and device specifications based on airway behavior and craniofacial geometry. - SMART Rx is a clinician-controlled guidance system that uses patient inputs, airway behavior patterns and stability testing results. - AIOMEGA said these tools guide prescriptions but do not modify the devices or their FDA-cleared indications. - Training modules cover adult and pediatric implementation pathways, multi segment collapsibility assessment, airway behavior interpretation, stability testing protocols and clinical documentation standards. - The Academy also covers guidance system training, the AIOMEGA Clinical Guidance System, AAVOAT and CAOM frameworks, one-and-done non-titrating regimens for appropriate adult patients, and clinical governance and QA guidance. - The Academy is designed for pediatric sleep medicine, ENT and pulmonology, dental sleep medicine, orthodontics, dentists specialized in TMD, hospital systems and youth athlete airway programs. - Founder Raghavendra Ghuge said clinicians want a clear, reproducible pathway for treating OSA with wearable oral devices that support airway stabilization. - Ghuge said the Academy connects the FDA-cleared adult and pediatric devices with a structured training system for safe, consistent implementation.

Between the lines: - AIOMEGA is positioning education and prescription workflow as part of the product, not just the device itself. - The emphasis on reproducibility, documentation and clinician-controlled guidance suggests the company is trying to reduce variability in how providers prescribe and monitor OSA treatment. - The release also frames the devices as usable across both medical and dental specialties, which could expand the company’s channel strategy.

What's next: - Clinicians and institutions can contact AIOMEGA to enroll in the Academy or explore device adoption. - AIOMEGA listed contact options at more information, info@aiomd.com and (903) 787-7533. - The company said the Academy will continue to support adult and pediatric implementation, training and clinical governance as adoption grows.

The bottom line: - AIOMEGA is bundling FDA-cleared OSA devices with a national clinician training program to push more standardized adoption across sleep, ENT and dental care.